Literature DB >> 23817558

Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.

Andreas P Lysandropoulos1, Fleur Benghiat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817558     DOI： 10.1177/1352458513493035

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  5 in total

Review 1.  Hemoglobins as new players in multiple sclerosis: metabolic and immune aspects.

Authors:  Meric A Altinoz; Emin M Ozcan; Bahri Ince; Sinan Guloksuz
Journal:  Metab Brain Dis       Date:  2016-05-28       Impact factor: 3.584

2.  Immune thrombocytopenic purpura associated with fingolimod.

Authors:  Hiu Lam Agnes Yuen; Susan Brown; Noel Chan; George Grigoriadis
Journal:  BMJ Case Rep       Date:  2017-09-11

3.  Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis.

Authors:  Ali Momeni; Rana Abrishamkar; Fatemeh Panahi; Sepehr Eslami; Nooshin Tavoosi; Aryan Rafiee Zadeh
Journal:  Am J Clin Exp Immunol       Date:  2019-08-15

Review 4.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

Review 5.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.